{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:01:04Z","timestamp":1781164864497,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.brachy.2025.10.012","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:14:17Z","timestamp":1763651657000},"page":"15-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2217-8477","authenticated-orcid":false,"given":"Jacob F.","family":"Oyeniyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-1723","authenticated-orcid":false,"given":"Joseph S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-6122","authenticated-orcid":false,"given":"Bailey A.","family":"Loving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirisha R.","family":"Nandalur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran R.","family":"Nandalur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-320X","authenticated-orcid":false,"given":"Evelyn L.","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Limbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2025.10.012_bib0001","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2012.07.040","article-title":"Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system","volume":"80","author":"Reese","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2025.10.012_bib0002","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-dose-rate monotherapy for localized prostate cancer: 10-year results","volume":"94","author":"Hauswald","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.012_bib0003","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer","volume":"36","author":"Spratt","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2025.10.012_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.brachy.2025.10.012_bib0005","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3389\/fonc.2020.00731","article-title":"Radiomics of multiparametric MRI to predict biochemical recurrence of localized prostate cancer after radiation therapy","volume":"10","author":"Zhong","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2025.10.012_bib0006","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s00066-020-01679-9","article-title":"The role of radiomics in prostate cancer radiotherapy","volume":"196","author":"Delgadillo","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"10.1016\/j.brachy.2025.10.012_bib0007","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.brachy.2024.10.008","article-title":"Mature effectiveness and toxicity outcomes associated with three treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer","volume":"24","author":"Salari","year":"2025","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.012_bib0008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.brachy.2016.11.002","article-title":"High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer","volume":"16","author":"Patel","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.012_bib0009","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.brachy.2014.03.002","article-title":"High-dose-rate brachytherapy as monotherapy for prostate cancer","volume":"13","author":"Demanes","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.012_bib0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.brachy.2023.05.002","article-title":"High-dose-rate brachytherapy as monotherapy versus as boost in unfavorable intermediate-risk localized prostate cancer: A matched-pair analysis","volume":"22","author":"Willen","year":"2023","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.012_bib0011","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2018.04.039","article-title":"Pretreatment multiparametric magnetic resonance imaging findings are more accurate independent predictors of outcome than clinical variables in localized prostate cancer","volume":"101","author":"Gomez-Iturriaga","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.012_bib0012","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s00261-024-04717-7","article-title":"Prognostic value of central gland volume on MRI for biochemical recurrence after prostate radiotherapy","volume":"50","author":"Lee","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.brachy.2025.10.012_bib0013","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.urolonc.2018.07.004","article-title":"Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer","volume":"36","author":"Kauffmann","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.brachy.2025.10.012_bib0014","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2214\/AJR.19.21836","article-title":"Prognostic value of pretreatment MRI in patients with prostate cancer treated with radiation therapy: A systematic review and meta-analysis","volume":"214","author":"Woo","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.brachy.2025.10.012_bib0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","article-title":"Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer","volume":"94","author":"Jawad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.012_bib0016","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.012_bib0017","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.brachy.2017.07.008","article-title":"Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy","volume":"16","author":"Hegde","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.012_bib0018","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2012.01.009","article-title":"Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy","volume":"84","author":"Riaz","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.012_bib0019","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.urolonc.2012.09.002","article-title":"The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes","volume":"32","author":"Mikel Hubanks","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.brachy.2025.10.012_bib0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jmri.25729","article-title":"Evaluation of MRI for diagnosis of extraprostatic extension in prostate cancer","volume":"47","author":"Krishna","year":"2018","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.brachy.2025.10.012_bib0021","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3348\/kjr.2019.0842","article-title":"The diagnostic performance of the length of tumor capsular contact on MRI for detecting prostate cancer extraprostatic extension: A systematic review and meta-analysis","volume":"21","author":"Kim","year":"2020","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.brachy.2025.10.012_bib0022","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/radiol.2018181278","article-title":"A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI","volume":"290","author":"Mehralivand","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.brachy.2025.10.012_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.012_bib0024","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2010.04.004","article-title":"Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer","volume":"80","author":"Krauss","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.012_bib0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brachy.2016.11.017","article-title":"American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review","volume":"16","author":"Keyes","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.012_bib0026","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijrobp.2025.01.022","article-title":"The benefit of short-term androgen deprivation therapy with radiation therapy for intermediate-risk prostate cancer","volume":"122","author":"Patel","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.012_bib0027","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: Results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2025.10.012_bib0028","article-title":"Trends in androgen deprivation use in men with intermediate-risk prostate cancer who underwent radiation therapy","volume":"7","author":"Agrawal","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2025.10.012_bib0029","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2024.05.026","article-title":"Variation in androgen deprivation therapy use among men with intermediate-risk prostate cancer: Results from a statewide radiation Oncology Quality Consortium","volume":"120","author":"Dykstra","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.012_bib0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijrobp.2018.08.030","article-title":"Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image guided radiation therapy without hormone therapy","volume":"103","author":"Berlin","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:39:42Z","timestamp":1781163582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472125003496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1538472125003496"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2025.10.012","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2025.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Brachytherapy Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}